Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Stock Is Skyrocketing 46.4% Higher Today

By Keith Speights - Mar 18, 2020 at 11:14AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are still excited about the biotech's coronavirus vaccine collaboration with Pfizer.

What happened

Shares of BioNTech (BNTX 1.32%) were skyrocketing 46.4% higher as of 11:07 a.m. EDT on Wednesday. This huge gain came after the biotech announced Tuesday that it and Pfizer (PFE 3.00%) would collaborate on developing a novel coronavirus vaccine

So what

BioNTech and Pfizer were already partners. The two companies signed an agreement in 2018 to collaborate on development of flu vaccines based on messenger RNA (mRNA). However, this week's expansion of the collaboration between BioNTech and Pfizer is an even bigger story because of the intense global focus on finding a way to slow the spread of the novel coronavirus and the disease that it causes, COVID-19.

Coronavirus vaccine bottles

Image source: Getty Images.

At this point, the financial details of the coronavirus collaboration haven't been worked out. That's not concerning, though. BioNTech and Pfizer now have a letter of intent in place related to the co-development and distribution (outside of China) of a coronavirus vaccine. 

Now what

BioNTech and Pfizer will start working together immediately on the coronavirus vaccine program. The companies plan to conduct research in both the U.S. and Germany. They expect to finalize the financial details of the agreement over the next few weeks.

Most importantly, the collaboration should accelerate the development of BioNTech's experimental COVID-19 mRNA vaccine, BNT162. This vaccine should begin clinical testing by the end of next month. But while BioNTech's shares are on a tear right now, look for significant volatility with the biotech stock as other companies make progress with their own novel coronavirus vaccine programs.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$134.04 (1.32%) $1.75
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.59 (3.00%) $1.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.